Precigen’s immunotherapy will likely reduce the need for repeat surgeries in recurrent respiratory papillomatosis (RRP) patients.

An update from Precigen ( ($PGEN) ) is now available. On August 18, 2025, Precigen, Inc. announced that its product PAPZIMEOS received FDA ...

Germantown: Precigen, Inc., a biopharmaceutical company specializing in the advancement of innovative precision medicines to ...

Papzimeos is the first and only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP), with ...

Shares in biopharmaceutical company Precigen (PGEN) rocketed higher today after the U.S. Food and Drug Administration gave ...

Earlier today, it was announced that Precigen’s PAPZIMEOS (formerly PRGN-2012) was FDA-approved for adults with RRP. Read why ...

For the first time, the FDA has approved a treatment for recurrent respiratory papillomatosis (RRP), a rare, chronic disease that causes benign tumors, most commonly in the voice box, and can force ...

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable results in clinical trials.

Precigen, Inc., a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the ...

US FDA approves Precigen’s Papzimeos for the treatment of adults with recurrent respiratory papillomatosis: Germantown, Maryland Monday, August 18, 2025, 17:00 Hrs [IST] Precige ...

Zopapogene imadenovec is a non-replicating adenoviral vector-based immunotherapy designed to induce an immune response against HPV 6 and HPV 11 proteins.

The FDA approved the adenoviral vector-based immunotherapy, zopapogene imadenovec-drba, for treatment of certain patients ...